Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies
European Journal of Clinical Microbiology & Infectious Diseases,
Год журнала:
2023,
Номер
42(12), С. 1405 - 1423
Опубликована: Окт. 28, 2023
Abstract
In
recent
years,
multidrug-resistant
Acinetobacter
baumannii
has
emerged
globally
as
a
major
threat
to
the
healthcare
system.
It
is
now
listed
by
World
Health
Organization
priority
one
for
need
of
new
therapeutic
agents.
A
.
capacity
develop
robust
biofilms
on
biotic
and
abiotic
surfaces.
Biofilm
development
allows
these
bacteria
resist
various
environmental
stressors,
including
antibiotics
lack
nutrients
or
water,
which
in
turn
persistence
hospital
environment
further
outbreaks.
Investigation
into
alternatives
that
will
act
both
biofilm
formation
antimicrobial
resistance
(AMR)
sorely
needed.
The
aim
present
review
critically
discuss
mechanisms
AMR
may
be
co-regulated
an
attempt
shed
light
paths
towards
novel
opportunities.
After
discussing
clinical
importance
,
this
critical
highlights
biofilm-formation
genes
associated
with
co-regulation
AMR.
Particularly
worthy
consideration
are
regulating
quorum
sensing
system
AbaI/AbaR,
AbOmpA
(OmpA
protein),
Bap
(biofilm-associated
two-component
regulatory
BfmRS,
PER-1
β-lactamase,
EpsA,
PTK.
Finally,
discusses
ongoing
experimental
strategies
fight
infections,
namely
vaccine
development,
interference,
nanoparticles,
metal
ions,
natural
products,
peptides,
phage
therapy.
better
understanding
co-regulate
help
identify
targets,
combined
approaches
confer
synergistic
benefits
effective
safer
treatments.
Язык: Английский
A novel mRNA multi-epitope vaccine of Acinetobacter baumannii based on multi-target protein design in immunoinformatic approach
BMC Genomics,
Год журнала:
2024,
Номер
25(1)
Опубликована: Авг. 19, 2024
Acinetobacter
baumannii
is
a
gram-negative
bacillus
prevalent
in
nature,
capable
of
thriving
under
various
environmental
conditions.
As
an
opportunistic
pathogen,
it
frequently
causes
nosocomial
infections
such
as
urinary
tract
infections,
bacteremia,
and
pneumonia,
contributing
to
increased
morbidity
mortality
clinical
settings.
Consequently,
developing
novel
vaccines
against
utmost
importance.
In
our
study,
we
identified
10
highly
conserved
antigenic
proteins
from
the
NCBI
UniProt
databases
for
epitope
mapping.
We
subsequently
screened
selected
8
CTL,
HTL,
LBL
epitopes,
integrating
them
into
three
distinct
constructed
with
adjuvants.
Following
comprehensive
evaluations
immunological
physicochemical
parameters,
conducted
molecular
docking
dynamics
simulations
assess
efficacy
stability
these
vaccines.
Our
findings
indicate
that
all
multi-epitope
mRNA
designed
are
promising;
however,
further
animal
studies
required
confirm
their
reliability
effectiveness.
Язык: Английский
A Semisynthetic Oligomannuronic Acid-Based Glycoconjugate Vaccine against Pseudomonas aeruginosa
ACS Central Science,
Год журнала:
2024,
Номер
10(8), С. 1515 - 1523
Опубликована: Июль 10, 2024
is
one
of
the
leading
causes
nosocomial
infections
and
has
become
increasingly
resistant
to
multiple
antibiotics.
However,
development
novel
classes
antibacterial
agents
against
multidrug-resistant
Язык: Английский
Design, development, and assessment of a novel multi-peptide vaccine targeting PspC, PsaA, and PhtD proteins of Streptococcus pneumoniae
Zohreh Bahadori,
Mona Shafaghi,
jahangir sabzevari
и другие.
International Journal of Biological Macromolecules,
Год журнала:
2023,
Номер
258, С. 128924 - 128924
Опубликована: Дек. 22, 2023
Язык: Английский
New Progress of Research on Vaccines against <i>Acinetobacter baumannii</i>
Advances in Clinical Medicine,
Год журнала:
2025,
Номер
15(05), С. 267 - 275
Опубликована: Янв. 1, 2025
Язык: Английский
A new candidate epitope-based vaccine against PspA PhtD of Streptococcus pneumoniae: a computational experimental approach
Mona Shafaghi,
Zohreh Bahadori,
Seyed Mahmoud Barzi
и другие.
Frontiers in Cellular and Infection Microbiology,
Год журнала:
2023,
Номер
13
Опубликована: Ноя. 15, 2023
Introduction
Pneumococcus
is
an
important
respiratory
pathogen
that
associated
with
high
rates
of
death
in
newborn
children
and
the
elderly.
Given
disadvantages
current
polysaccharide-based
vaccines,
most
promising
alternative
for
developing
improved
vaccines
may
be
to
use
protein
antigens
different
roles
pneumococcus
virulence.
PspA
PhtD,
highly
immunogenic
surface
proteins
expressed
by
almost
all
pneumococcal
strains,
are
capable
eliciting
protective
immunity
against
lethal
infections.
Methods
In
this
study
using
immunoinformatics
approaches,
we
constructed
one
fusion
construct
(called
PAD)
fusing
immunodominant
regions
from
families
1
&
2
(PA)
PhtD
(PD).
The
objective
project
was
test
immunogenicity
PAD
compare
its
activity
S.
pneumoniae
infection
PA
or
PD
alone
a
combination
PD.
prediction
physicochemical
properties,
antigenicity,
allergenicity,
toxicity,
3D-structure
constructs,
as
well
molecular
docking
HLA
receptor
immune
simulation
were
performed
computational
tools.
Finally,
mice
immunized
serum
levels
antibodies/cytokines
functionality
antibodies
vitro
evaluated
after
immunization.
survival
decrease
bacterial
loads
blood/spleen
examined
following
challenge.
Results
analyses
indicated
proposed
constructs
could
antigenic,
non-allergenic,
non-toxic,
soluble
able
elicit
robust
responses.
results
actual
animal
experiments
revealed
candidate
induce
produce
cytokines.
complement-mediated
bactericidal
confirmed
provided
favorable
general,
experimental
verified
studies.
Conclusion
For
first
time
report
presents
novel
peptide-based
vaccine
candidates
consisting
antigens.
obtained
findings
formulation
relatively
more
efficient
than
individual
formulations.
propose
used
serotype-independent
effective
partner
conjugate
polysaccharide
vaccine.
Язык: Английский
Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model
Immunology Letters,
Год журнала:
2023,
Номер
262, С. 18 - 26
Опубликована: Авг. 29, 2023
Язык: Английский
Investigation of plant metabolites as potential inhibitors of Acinetobacter baumannii: An In-Silico approach
Informatics in Medicine Unlocked,
Год журнала:
2023,
Номер
41, С. 101343 - 101343
Опубликована: Янв. 1, 2023
The
gram-negative
bacteria
Acinetobacter
baumannii
is
responsible
for
a
broad
spectrum
of
dangerous
nosocomial
infections.
easily
transmitted
into
the
body
via
mechanical
ventilators,
open
wounds,
and
intravascular
catheters.
Bloodstream
infections
ventilator-associated
pneumonia
caused
by
A.
have
greatest
mortality
rates.
Due
to
its
multidrug
resistance
(MDR),
drug
resistance,
pan-drug
phenotypes,
now
recognized
as
particularly
challenging
pathogen
control.
In
order
develop
novel
therapeutics
existing
condition,
an
in-silico
approach
was
used.
Based
on
review
literature,
five
target
proteins
including
OmpA
(Peptidoglycan-binding
domain),
CarO,
DcaP,
OmpW,
PBP
were
identified
be
vital
pathogen's
survival,
infection
host,
resistance.
A
total
20
potential
plant
metabolites
with
antibacterial
properties
docked
against
these
proteins.
Among
them,
Corilagin,
-(+)-Lyoniresinol-3
alpha-O-beta-d-glucopyranoside,
Epsilon-Viniferin,
Epigallocatechin
gallate
(EGCG)
showed
superior
binding
energy
compared
reference
carbapenem.
Corilagin
alpha-O-beta-d-glucopyranoside
best
DcaP
protein
having
docking
score
about
−261.74,
−238.19
respectively.
Those
two
protein-ligand
complexes
assessed
MS
simulation
where
average
RMSD
value
3.5
A°
Dcap-Corilagin
3.0
Dcap-(+)-Lyoniresinol-3
indicated
their
excellent
stability.
In-silico
ADME
analysis
all
four
had
good
estimated
solubility
(ESOL)
between
−3.56
−6.32,
Log
P
range
1.87–2.71
they
responded
negatively
in
Blood-Brain
Barrier,
CYP
inhibition.
Toxicity
study
that
expected
new
drugs,
are
completely
non-carcinogenic,
non-toxic,
safe
use
therapeutic
treatments
baumannii.
Therefore,
predicted
could
used
medication
As
result
promising
outcomes
from
our
present
study,
we
strongly
recommend
more
vivo
experimental
confirmation.
Язык: Английский